Klotho Neurosciences Aktie News

Aktie
WKN:  A40KLP ISIN:  US49876K1034 US-Symbol:  KLTO Branche:  Biotechnologie Land:  USA
0,2611 $
-0,0079 $
-2,94%
0,22067 € 03.02.26
Depot/Watchlist
Marktkapitalisierung *
9,57 Mio. €
Streubesitz
76,14%
KGV
-
Index-Zuordnung
-

Klotho Neurosciences News

08.01.26 - PR Newswire
Klotho Neurosciences to Present at the Biotech Showcase 2026
Klotho Neurosciences to Present at the Biotech Showcase 2026 PR Newswire
07.11.25 - PR Newswire
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award PR Newswire
16.10.25 - PR Newswire
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire
07.10.25 - PR Newswire
Klotho Neurosciences Announces Expiration of Letter of Intent
Klotho Neurosciences Announces Expiration of Letter of Intent PR Newswire
30.09.25 - PR Newswire
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership PR Newswire
09.09.25 - PR Newswire
CEO von Klotho Neurosciences nimmt an Eröffnungskonferenz und wissenschaftlichem Seminar teil
CEO von Klotho Neurosciences nimmt an Eröffnungskonferenz und wissenschaftlichem Seminar teil PR Newswire
08.09.25 - PR Newswire
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar PR Newswire
08.09.25 - PR Newswire
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar PR Newswire
18.08.25 - PR Newswire
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market PR Newswire
12.08.25 - PR Newswire
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology PR Newswire
25.07.25 - PR Newswire
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology PR Newswire
24.07.25 - PR Newswire
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology PR Newswire
22.07.25 - PR Newswire
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets PR Newswire
16.07.25 - PR Newswire
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules PR Newswire
10.07.25 - PR Newswire
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") PR Newswire
30.06.25 - PR Newswire
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS PR Newswire
30.06.25 - PR Newswire
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS PR Newswire
24.06.25 - PR Newswire
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the ...
24.06.25 - PR Newswire
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the ...
18.06.25 - PR Newswire
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS ...

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »